



## QSAM BIOSCIENCES, INC.

Stock Up 33% Since Initiation; New Catalysts Lead to Higher Prices

Rob Goldman  
[rob@goldmanresearch.com](mailto:rob@goldmanresearch.com)

January 29, 2021

### QSAM BIOSCIENCES, INC. (OTCQB – QSAM - \$0.80)

Industry: Biotechnology

Price Target: \$3.00

#### COMPANY SNAPSHOT

QSAM is developing next generation nuclear medicines for the treatment of cancer and related diseases and conditions with high unmet need. The Company's flagship product, *Cyclosam*<sup>®</sup>, is a clinical-stage bone seeking therapeutic radiopharmaceutical designed to safely and specifically deliver targeted radiation therapy to kill cancer cells in and near the bone. In animal studies and a recent single patient human trial, this approach appears to improve efficacy and safety. QSAM plans to commence additional trials during 2021.

#### KEY STATISTICS

Price as of 1/28/21	\$0.80
52 Week High – Low	\$2.10- \$0.15
Current Shares Outstanding	19.6M
Current Market Capitalization	\$15.7M
Average Volume	56,604
Exchange	OTCQB

#### COMPANY INFORMATION

##### QSAM Biosciences, Inc.

420 Royal Palm Way  
 #100  
 Palm Beach, FL 33480

Web: [www.QSAMBio.com](http://www.QSAMBio.com)  
 Email: [dbaum@qsambio.com](mailto:dbaum@qsambio.com)  
 Phone : 512.799.9397

#### INVESTMENT HIGHLIGHTS

**Latest News—Funding for Phase I Clinical Trial.** QSAM announced it raised \$2.5M via the closing of an oversubscribed Series B Convertible Preferred Stock private placement led by Checkmate Capital. The funding also includes warrants to purchase QSAM's common stock. Proceeds will primarily be used to fund its upcoming clinical trial.

**What it Means:** With R&D funds in hand, the stock is markedly de-risked and should enjoy future rises given that next stage milestones are around the corner. As an early-stage biotech, each milestone event typically leads to re-valuations and higher stock prices.

**What's Next:** During 1Q21, QSAM plans to file an IND for its lead radiologic cancer therapy *Cyclosam*<sup>®</sup>, with a Phase I clinical trial to launch shortly thereafter. During 2021, a series of *Cyclosam*<sup>®</sup> clinical trial commencements could occur representing indications including primary bone cancer, such as osteosarcoma, and secondary bone cancers that metastasize from the breast, lung, and prostate.

**Reiterating our \$3.00 Target.** We initiated coverage about two weeks ago and the stock is up 33%, aided in part by very favorable study results. With the funding in place for its upcoming trial, favorable studies, and future clinical trials launches on the horizon, we view QSAM's current price as an attractive entry point for opportunistic investors.

## Recent Trading History For QSAM

(Source: [www.BigCharts.com](http://www.BigCharts.com))





## SENIOR ANALYST: ROBERT GOLDMAN

Rob Goldman founded Goldman Small Cap Research in 2009 and has over 25 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and *The Blue and White Fund*.

## ANALYST CERTIFICATION

I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.

## DISCLAIMER

This *Opportunity Research* report was prepared for informational purposes only.

*Goldman Small Cap Research*, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: *Goldman Select Research* and *Goldman Opportunity Research*. The *Select* format reflects the Firm's internally generated stock ideas along with economic and stock market outlooks. *Opportunity Research* reports, updates and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored micro-cap research ideas that typically carry greater risks than those stocks covered in the *Select Research* category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Research reports on profiled stocks in the *Opportunity Research* format typically have a higher risk profile and may offer greater upside. *Goldman Small Cap Research* was compensated by a third party in the amount of \$7500 for research report and research update production and distribution, including a press release. All information contained in this report was provided by the Company via filings, press releases or its website, or through our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.

Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Such information and the opinions expressed are subject to change without notice.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. *Goldman Small Cap Research* did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. *Goldman Small Cap Research* relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such



information and the opinions expressed are subject to change without notice. A *Goldman Small Cap Research* report or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. This report does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor's decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither *Goldman Small Cap Research*, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED "AS IS" WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, *TWO TRIANGLE CONSULTING GROUP, LLC* WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, *TWO TRIANGLE CONSULTING GROUP, LLC* WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: [www.goldmanresearch.com](http://www.goldmanresearch.com)